% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • dcaf7 dcaf7 Jun 1, 2013 8:46 AM Flag

    Great data on uveal melanoma presented at ASCO

    Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).
    Sel (n=27): median PFS 16 wks (95% CI 8-30.9), RR 11%, median OS 11.8 months (95% CI 4.8-not reached). TMZ (n=28): median PFS 4 wks (95% CI 3.7-15), RR 0%, median OS 4.7 months (95% CI 4.3-14.3).
    Conclusions: Sel is the first drug to ever show improved clinical activity in UM relative to TMZ. Sustained target inhibition is observed with sel. Final results will be presented.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.74-0.03(-0.80%)Jul 29 4:00 PMEDT